Jerusalem, Israel – Feb 14, 2019
NovellusDx team will be attending the AACR 2019 annual meeting and will present a poster titled: “Accurate prediction of the signaling pathway activity elicited by Variants of Uncertain Significance (VUS) and their drug sensitivity using Deep Convolutional Neural Networks on fluorescent microscopy images of cells”.
The poster session will take place on Monday April 1st 1:00 PM – 5:00 PM at the Georgia World Congress Center, Exhibit Hall B, Poster Section 30.
NovellusDx’s mission is to provide functional information about mutations and their responses to drugs so that oncologists can treat patients with precision therapies and bio-pharmaceutical companies can develop drugs more effectively. The NovellusDx approach is to monitor the functional effects of mutations and observe the effects of drugs, drug combinations and drug candidates on the activity level caused by the mutations. NovellusDx’s headquarters and research and development operations are based in Jerusalem, Israel.
To learn more about NovellusDx please visit www.novellus.bio